Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s share price traded down 4.3% on Wednesday . The company traded as low as $15.51 and last traded at $15.32. 23,687 shares traded hands during trading, a decline of 87% from the average session volume of 187,526 shares. The stock had previously closed at $16.01.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the company. TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They set a "buy" rating for the company. Cantor Fitzgerald started coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an "overweight" rating and a $50.00 price target on the stock. Wells Fargo & Company started coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 price target on the stock.
Check Out Our Latest Stock Analysis on SEPN
Septerna Trading Down 4.0 %
The firm has a 50-day moving average of $22.02.
Hedge Funds Weigh In On Septerna
A hedge fund recently bought a new stake in Septerna stock. SG Americas Securities LLC purchased a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,095 shares of the company's stock, valued at approximately $185,000.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
